Effect of Injection Site on the Relative Bioavailability of a Single Dose of RAY1225 in Subjects With Low and High Body Mass Index
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- PK: Maximum Concentration (Cmax) of RAY1225
Study Overview
Brief Summary
The purpose of this study is to compare the amount of RAY1225 that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of RAY1225 will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 7 weeks, including screening.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Body mass index (BMI) ≥19 kg/m2 and total body weight >50 kg for male, >45 kg for female at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
- •Ability to understand and willingness to sign a written informed consent form;
- •Normal physical examination, vital signs, 12-lead ECG, and clinical laboratory values, or any abnormality that is non-clinically significant.
Exclusion Criteria
- •Participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the investigational drug product or any component of the investigational drug product;
- •Participants had taken prescription, over-the-counter, herbal, or vitamin products within 14 days prior to screening；
- •Smoking more than 5 cigarettes per day within 3 months prior to screening，or who cannot stop using any tobacco products during the study period;
- •Participants who donated blood/bleeding profusely (> 400 mL) 3 months prior to randomization;
- •Those with clinically significant Electrocardiogram(ECG) abnormalities, or QTcF > 450ms;
- •Participants who test positive at screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or Syphilis spirochete-specific antibodies (TPPA);
- •Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse.
- •Females who are pregnant, lactating, or likely to become pregnant during the study.
- •History of dysphagia or any gastrointestinal disorder that affect absorption;
- •Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
Arms & Interventions
RAY1225 - Upper Arm
Participants received 3mg RAY1225 by subcutaneous injection on upper arm.
Intervention: RAY1225 (Drug)
RAY1225 - Thigh
Participants received 3mg RAY1225 by subcutaneous injection on thigh.
Intervention: RAY1225 (Drug)
RAY1225 - Abdomen
Participants received 3mg RAY1225 by subcutaneous injection on abdomen.
Intervention: RAY1225 (Drug)
Outcomes
Primary Outcomes
PK: Maximum Concentration (Cmax) of RAY1225
Time Frame: DAY1~43
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of RAY1225 From Time Zero to Infinity (AUC[0-∞])
Time Frame: DAY1~43
Secondary Outcomes
- Number of participants with adverse events(DAY1~43)